Command Palette

Search for a command to run...

Clinical Trials · NCT00620282

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
49
Start date
Feb 2008
Locations
1 site, United States
Primary endpoint
Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)
View Liraglutide compound reference